Biomatics Capital related stories
All articles and analysis
GV leads Series A round for Verve TherapeuticsCambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has raised $58.5 million in Series A funding. GV led the round with participation from ARCH Venture Partners, F-Prime Capital and Biomatics Capital.
- Verana Health inks $30 mln Series C
Verana Health, a healthcare innovation platform, has raised $30 million in Series C financing. GV led the round with participation from return backers Biomatics Capital, Brook Byers, GE Ventures and Lagunita Biosciences. In addition to the funding, Verana Health has appointed Miki Kapoor as president and CEO.
- Compass Therapeutics closes $132 mln Series A
Cambridge, Massachusetts-based Compass Therapeutics, a biotechnology company, has closed its $132 million Series A financing. OrbiMed Advisors led the round with participation from other investors that included F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Ulysses Holdings, Borealis Ventures, Alexandria Venture Investments and Biomed Realty Ventures.
- Cytrellis Biosystems seals $28.5 mln Series B
Woburn, Massachusetts-based Cytrellis Biosystems, a medical technology company that's developing new aesthetic devices, has secured $28.5 million in Series B funding. The investors included ARCH Venture Partners, the Merz Venture Initiative, Partner Fund Management and BioMatics Capital.
- Biomatics Capital targets $300 mln for second venture fund
Biomatics Capital is raising a second venture fund targeting $300 million, according to a regulatory filing https://www.sec.gov/Archives/edgar/data/1740118/000174011818000001/xslFormDX01/primary_doc.xml The Seattle-based firm is led by Julie Sunderland, who previously served as the director of program related investments for the Bill & Melinda Gates Foundation, and Boris Nikolic, previously the chief advisor for science and technology to Bill Gates, according to the firm’s website https://www.biomaticscapital.com/#team
- DNA synthesis provider Twist Bioscience attracts $27 mln
San Francisco-based Twist Bioscience, a provider of DNA synthesis, has raised $27 million in funding. The investors were Biomatics Capital, Reinet Fund S.C.A., F.I.S., NFT Investment Limited, KANGMEI Group, Bay City Capital GF Xinde Life Science Investment Fund, 3W Partners Capital and Ditch Plains Capital Management LP.
- eGenesis attracts $38 mln Series A
Cambridge, Massachusetts-based eGenesis, a biotechnology company, has raised $38 million in Series A financing. Biomatics Capital and ARCH Venture Partners led the round with participation from Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd, Uprising, and Fan Ventures. In conjunction with the funding, Daniel S. Lynch was appointed executive chairman of eGenesis.
- Aledade collects $20 mln
Bethesda, Maryland-based Aledade, which helps doctors form and operate accountable care organizations, has raised $20 million in funding. Biomatics Capital led the round with participation from other investors that included GV, Maryland Venture Fund, Venrock and ARCH Venture Partners.